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The intrinsic, or mitochondrial, pathway of caspase activation is essential for apoptosis induction by various stimuli
including cytotoxic stress. It depends on the cellular context, whether cytochrome c released from mitochondria
induces caspase activation gradually or in an all-or-none fashion, and whether caspase activation irreversibly commits
cells to apoptosis. By analyzing a quantitative kinetic model, we show that inhibition of caspase-3 (Casp3) and Casp9
by inhibitors of apoptosis (IAPs) results in an implicit positive feedback, since cleaved Casp3 augments its own
activation by sequestering IAPs away from Casp9. We demonstrate that this positive feedback brings about bistability
(i.e., all-or-none behaviour), and that it cooperates with Casp3-mediated feedback cleavage of Casp9 to generate
irreversibility in caspase activation. Our calculations also unravel how cell-specific protein expression brings about the
observed qualitative differences in caspase activation (gradual versus all-or-none and reversible versus irreversible).
Finally, known regulators of the pathway are shown to efficiently shift the apoptotic threshold stimulus, suggesting
that the bistable caspase cascade computes multiple inputs into an all-or-none caspase output. As cellular inhibitory
proteins (e.g., IAPs) frequently inhibit consecutive intermediates in cellular signaling cascades (e.g., Casp3 and Casp9),
the feedback mechanism described in this paper is likely to be a widespread principle on how cells achieve
ultrasensitivity, bistability, and irreversibility.
Citation: Legewie S, Blu ¨thgen N, Herzel H (2006) Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. PLoS Comput Biol
2(9): e120. DOI: 10.1371/journal.pcbi.0020120
Introduction
Apoptosis, an evolutionary conserved form of cell suicide,
allows multicellular organisms to eliminate damaged or
excess cells in order to maintain tissue homeostasis. Dysre-
gulation of apoptosis is associated with various pathological
conditions, including cancer and neurodegenerative disor-
ders. Aspartate-speciﬁc cysteine proteases, also known as
caspases, are the central executioners of apoptosis. In most
cases, apoptotic stimuli activate initiator caspases, whose
substrates, the effector caspases, ultimatively cause cellular
demise by cleaving various cellular substrates [1].
Figure 1A schematically depicts the so-called extrinsic and
intrinsic apoptotic pathways that elicit apoptosis by cleaving
and thereby activating caspase-3 (Casp3), the major cellular
effector caspase. The extrinsic pathway is initiated by ligand-
binding to death receptors (e.g., CD95), which then oligo-
merize and recruit various proteins, including pro-Casp8,
into the so-called death-inducing signaling complex. For-
mation of the death-inducing signaling complex leads to
autoprocessing of pro-Casp8 into active (initiator) Casp8,
which then cleaves (effector) Casp3. Cytotoxic stress or death-
receptor–stimulated Casp8 engage the intrinsic, or mitochon-
drial, apoptosis pathway by inducing the translocation of
proapoptotic Bcl-2 family members such as Bax and Bid to
mitochondria. This event, which is negatively regulated by
antiapoptotic Bcl-2 family members (e.g., Bcl-2), results in the
release of proapoptotic proteins (cytochrome c [cyto c] and
Smac) from mitochondria into the cytosol. Cytosolic cyto c
then elicits the oligomerization of Apaf-1 into an active high-
molecular-weight complex, the apoptosome, which recruits
and stimulates (initiator) Casp9, and thereby allows activation
of effector caspases such as Casp3. Smac and inhibitors of
apoptosis (IAPs) such as X-linked IAP (XIAP) establish an
additional layer of regulation in the intrinsic pathway: XIAP
inhibits the catalytic activities of Casp9 and Casp3 through
reversible binding, and cytosolic Smac relieves this inhibition
by sequestering XIAP away from caspases [2].
Experimental studies revealed that the qualitative behav-
iour of caspase activation in the intrinsic pathway depends on
the cellular context. Cyto c added to cytosolic extracts
activates Casp3 in an all-or-none fashion in some cells [3–
7], while gradual activation was observed in other systems [8–
10]. As cyto-c release from mitochondria can be a reversible
event [11], which does not affect mitochondrial function [12–
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irreversibly commits cells to apoptosis [15,16]. Accordingly,
cyto c–induced Casp3 activation remained elevated even after
a strong decline in cytosolic cyto c [17] or after apo–cyto c, an
inhibitor of apoptosome formation, was added [18]. Further-
more, the time course of caspase activation via the intrinsic
pathway equals that for irreversible commitment to apoptosis
[15,16], and caspase-inhibition allows for long-term cellular
recovery and/or proliferation after removal of apoptotic
stimuli [15,16,19–22]. Finally, Fas-treated Jurkat T cells, which
enter apoptosis by the intrinsic pathway, escaped commit-
ment to death as judged by maintenance of clonogenic
potential if Casp3 was inhibited [23]. On the contrary, Casp3
activation was found to be a reversible event in glycocheno-
deoxycholate-treated hepatocytes [24].
These qualitative differences in caspase activation suggest
that the intrinsic pathway is bistable in some cells, but
monostable in others. While simple monostable systems
respond in a gradual and reversible manner, complex bistable
systems exhibit true all-or-none responses and in some cases
irreversibility. Bistability is thought to require a positive
circuit, which may be established either by positive feedback
or by double-negative feedback. Once a threshold stimulus is
exceeded, such positive circuits allow bistable systems to
switch from low activation levels (off state) to high activation
levels (on state) in an all-or-none fashion. Bistable systems
display hysteresis, meaning that different stimulus-response
curves are obtained depending upon whether the system
began in its off or its on state. In some cases, the on state is
maintained indeﬁnitely after the stimulus is removed, so that
the system shows irreversible activation [25]. Experimental
studies conﬁrmed that bistability indeed occurs in natural
and artiﬁcial biological networks [25–29].
Recent mathematical modeling demonstrated that bistability
can arise from ‘‘hidden,’’ or implicit, feedback loops that are
usually not explicitly drawn in biochemical reaction schemes
[30,31]. Similarily, we present a model showing that inhibition of
Casp3 and Casp9 by IAPs results in an implicit positive feedback
and in bistability. As cellular inhibitory proteins (e.g., IAPs)
frequently inhibit consecutive intermediates in cellular signaling
cascades (e.g., Casp3 and Casp9), the mechanism described in this
paper is likely to be a widespread principle on how cells achieve
ultrasensitivity, bistability, and irreversibility (Protocol S5).
Results
Model Derivation
Based on the published literature, we derived a core model
of the intrinsic apoptosis pathway, which includes general
Figure 1. Mathematical Model of the Intrinsic Apoptosis Pathway
(A) Schematic representation of intrinsic and extrinsic apoptosis pathways.
Dotted lines indicate positive (green) or negative (red) regulation, and the
solid lines refer to release of Smac and cyto c from mitochondria. The
regulatory interactions considered in the model are highlighted in gray. The
numbers 1–4 refer to additional feedbacks described in the Discussion.
(B) Kinetic scheme of the model. The reactions depicted in gray, which
are involved in Casp3-mediated feedback cleavage of Casp9, were
eliminated in the Casp9-mutant model in order to dissect the role of
XIAP-mediated feedback.
A*, activated Apaf-1; C3, Casp3; C9, Casp9.
DOI: 10.1371/journal.pcbi.0020120.g001
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Synopsis
Multicellular organisms eliminate damaged or excess cells by
programmed cell death, also known as apoptosis. By modelling the
signalingpathwaysinvolvedintheinitiationofapoptosis,theauthors
provide insight into how cells prevent spontaneous apoptosis, but
yet efficiently enter cell death, once proapoptotic signals exceed a
threshold. The simulations also explain how cells accurately translate
a complex set of pro- and anti-apoptotic signals into a life-or-death
decision. Once apoptosis has been initiated, cellular demise must
irreversibly proceed even if the initial trigger is removed, as partial
cellular disintegration might lead to tissue inflammation or cellular
deregulation. The authors explain how such irreversible commitment
arises in the initiation pathways of apoptosis and provide exper-
imentally testable predictions. Finally, the simulations reveal an
unanticipated role for the inhibitor of apoptosis family of proteins, as
these proteins are predicted to be involved in the amplification of
death signals and not only in their suppression.
Bistability in Caspase Activationregulatory mechanisms, while cell-type–speciﬁc events were
not taken into account. The gray-shaded area in Figure 1A
indicates the regulatory interactions considered in the model:
active Apaf-1, which was taken as the input in most
simulations, recruits and thereby stimulates (initiator) Casp9.
Casp9 then in turn activates the output species, (effector)
Casp3, by proteolytic processing. In addition, Casp3-medi-
ated cleavage of Casp9 results in positive feedback ampliﬁ-
cation. Finally, both Casp3 and Casp9 are subject to
stoichiometric inhibition by IAPs. For simplicity, we consid-
ered only the most potent caspase inhibitor among the IAP
family of proteins, XIAP. The corresponding kinetic scheme
is depicted in Figure 1B.
Cyto c released from mitochondria is known to elicit
heptamerization of Apaf-1 into active apoptosomes. As
detailed kinetic measurements of apoptosome formation
are currently lacking, apoptotic stimulation was modeled by
altering the total concentration of activated Apaf-1 molecules
assembled in apoptosomes (A*tot ¼ A* þ A*C9 þ A*C9X þ
A*C9*þA*C9*X). Each active Apaf-1 monomer assembled in
apoptosomes was shown to reversibly bind to a single Casp9
molecule [32], and Casp9 is then autoproteolytically pro-
cessed at amino acid Asp-315 [33]. Importantly, Casp9
autoproteolysis does not affect either enzymatic activity of
Casp9 [34] or its recruitment to apoptosomes [35,36]. Because
of these data, we did not distinguish between autoproteolyti-
cally processed and unprocessed Casp9 in the model.
The enzymatic activity of Casp9 is thought to be deter-
mined mainly by apoptosome recruitment, as apoptosome-
bound Casp9 was shown to be much more active than free
Casp9 [37,38]. Therefore, we assumed in the model that
reversible association of Casp9 (C9) and Apaf-1 (A*) (reaction
1) yields a highly active Apaf1–Casp9 complex (A*C9), which
cleaves pro-Casp3 (C3) much more efﬁciently (reaction 3)
than free Casp9 (reaction 2; see Table 1). The latter reaction
was nevertheless taken into account, since free Casp9 was
shown to have signiﬁcant basal activity towards pro-Casp3
[32].
Processing of pro-Casp3 into mature Casp3 by upstream
initiator caspases such as Casp9 was reported to occur by a
sequential two-step mechanism: Pro-Casp3, which has negli-
gible enzymatic activity [39], is initially processed by Casp9
into active p12-p20-Casp3, and this intermediate is subse-
quently autocatalytically cleaved into active p12-p17-Casp3
[40]. As shown in Figure 1B, we modeled Casp3 activation by a
single-step mechanism (C3 ! C3*). This seems justiﬁed, as
the p12-p20-Casp3 intermediate and mature p12-p17-Casp3
exhibit similar catalytic activities [41], and as they are both
subject to inhibition by XIAP (see below).
Casp3 is known to cleave its own activator, Casp9, at amino
acid Asp-330 in vitro [34,42], and in cytosolic extracts treated
with cyto c [5,33]. As Casp9 processing by Casp3 was shown to
signiﬁcantly enhance Casp9 activity [34], feedback cleavage by
Casp3 results in autoampliﬁcation of the apoptotic signal.
Table 1. Kinetic Parameters
Number Reaction kþ k  k /k þ
1C 9 þ A* $ A*C9 2 3 10
 3 nM
 1s
 1 0.1 s
 1 50 nM [32]
2C 3 þ C9 ! C3* þ C9 5 3 10
 6 nM
 1s
 1 [32] — —
3C 3 þ A*C9 ! C3* þ A*C9 3.5 3 10
 4 nM
 1s
 1 (70 times number 2 [37]) — —
4C 9 þ C3* ! C9* þ C3* 2 3 10
 4 nM
 1s
 1 [107] — —
5 A*C9 þ C3* ! A*C9* þ C3* 2 3 10
 4 nM
 1s
 1 (same as number 4) — —
6C 3 þ C9* ! C3* þ C9* 5 3 10
 5 nM
 1s
 1 (10 times number 2 [34]) — —
7C 3 þ A*C9* ! C3* þ A*C9* 3.5 3 10
 3 nM
 1s
 1 (10 times number 3 [34]) [109] — —
8 C9* þ A* $ A*C9* 2 3 10
 3 nM
 1s
 1 (same as number 1) 0.1 s
 1 (same as number 1) 50 nM
9C 9 þ X $ C9X 10
 3 nM
 1s
 1 10
 3 s
 1 1 nM [2,34]
10 A*C9 þ X $ A*C9X 10
 3 nM
 1s
 1 (same as number 9) 10
 3 s
 1 (same as number 9) 1 nM
11 C9* þ X $ C9*X 10
 3 nM
 1s
 1 (same as number 9) 10
 3 s
 1 (same as number 9) 1 nM
12 A*C9* þ X $ A*C9*X 10
 3 nM
 1s
 1 (same as number 9) 10
 3 s
 1 (same as number 9) 1 nM
13 C9X þ A* $ A*C9X 2 3 10
 3 nM
 1s
 1 (same as number 1) 0.1 s
 1 (same as number 1) 50 nM
14 C9*X þ A* $ A*C9*X 2 3 10
 3 nM
 1s
 1 (same as number 1) 0.1 s
 1 (same as number 1) 50 nM
15 C3* þ X $ C3*X 3 3 10
 3 nM
 1s
 1 [45] 10
 3 s
 1 [45] 0.3 nM [45,46,106,108]
16 A*$ 10
 3 s
 1 0.02 nM s
 1 (adjusted) 20 nM [51]
17 C9$ 10
 3 s
 1 (same as number 16) 0.02 nM s
 1 (adjusted) 20 nM [51]
18 X$ 10
 3 s
 1 (same as number 16) 0.04 nM s
 1 (adjusted) 40 nM [35,50,52]
19 C9X ! 10
 3 s
 1 (same as number 16) — —
20 A*C9X ! 10
 3 s
 1 (same as number 16) — —
21 A*C9 ! 10
 3 s
 1 (same as number 16) — —
22 C3$ 10
 3 s
 1 (same as number 16) 0.2 nM s
 1 (adjusted) 200 nM [52,53]
23 C3* ! 10
 3 s
 1 (same as number 16) — —
24 C3*X ! 10
 3 s
 1 (same as number 16) — —
25 C9*X ! 10
 3 s
 1 (same as number 16) — —
26 C9* ! 10
 3 s
 1 (same as number 16) — —
27 A*C9* ! 10
 3 s
 1 (same as number 16) — —
28 A*C9*X ! 10
 3 s
 1 (same as number 16) — —
The reactions numbered according to Figure 1B (Number) are listed, and the corresponding reactants and products are indicated (Reaction). The kþcolumn contains the rate constants of
the reactions from left to right, and the k column contains those for the opposite direction. The ratio of kþ/k equals the dissociation constant for reversible bimolecular reactions, while
it refers to the steady-state protein concentration for synthesis and degradation reactions (numbers 16–18 and number 22). Similar reactions were assumed to proceed with same kinetics
as indicated below the parameter values.
—, no values.
DOI: 10.1371/journal.pcbi.0020120.t001
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Bistability in Caspase ActivationThe physiological relevance of this positive feedback loop was
conﬁrmed in several studies, which showed that inhibition of
Casp3-mediated cleavage of Casp9 prevented full activation
of both Casp3 and Casp9 in response to cyto c [34,43,44].
Casp3-mediated feedback processing of Casp9 was mod-
eled by assuming that active Casp3 (C3*) cleaves both free
and Apaf1-associated Casp9 (reactions 4 and 5), thereby
generating the Asp330-cleaved Casp9 species, C9* and
A*C9*. These feedback-cleaved Casp9 species in turn cleave
pro-Casp3 more efﬁciently (reactions 6 and 7; see Table 1)
when compared with their precursors, C9 and A*C9*, thus
establishing a feedback ampliﬁcation loop. Feedback-pro-
cessed Casp9 (cleaved at Asp330) was shown to be associated
with apoptosomes [34,36], much like its precursors that are
not cleaved at Asp330 (see above). Therefore, we assumed in
the model that the kinetics of Casp9-binding to Apaf-1
(reactions 1 and 8) are unaffected by Casp3-mediated
feedback cleavage (see Table 1).
IAPs such as XIAP act as stoichiometric inhibitors of Casp3
and Casp9 [2], and accordingly caspase inhibition can be
described by simple reversible binding [45,46]. Experimental
evidence suggests that XIAP can bind to and inhibit Casp9,
even if the latter is associated with apoptosomes [34].
Accordingly, we assumed in the model that active Apaf-1
(A*) and XIAP (X) bind to Casp9 in a noncompetitive manner
so that Apaf1-bound Casp9 intermediates (A*C9 and A*C9*)
recruit XIAP with the same kinetics as free Casp9 (C9 and
C9*). In addition, we modeled XIAP binding to Casp9 such
that it is not affected by either Casp9 autocleavage (at Asp-
315) or Casp3-mediated feedback cleavage (at Asp-330). As
contradictory experimental results were obtained on how
Casp9 cleavage modulates inhibition by XIAP, the impact of
the latter assumption will be stressed in the Discussion.
Because of the assumptions made in the previous para-
graph, there is reversible recruitment of XIAP to all Casp9
species in the model (reactions 9–12), and also free exchange
of Apaf1 between the resulting Casp9–XIAP complexes
(reactions 13–14). All Casp9–XIAP complexes were assumed
to be catalytically inactive, which is in accordance with
experimental studies [47,48]. Furthermore, Casp3-mediated
feedback processing of XIAP-bound Casp9 was neglected in
the model, as the Casp9–XIAP binding interface is nearby the
corresponding cleavage site (Asp-330) [48].
It is well established that XIAP binds both to partially
processed Casp3 (p12-p20) and to mature Casp3 (p12-p17),
but not to its inactive precursor pro-Casp3 [46,49]. In
accordance with experimental data [45,46], reversible associ-
ation between Casp3 and XIAP (reaction 15) was modeled to
result in a catalytically inactive complex (C3*X). Due to the
enzymatic inactivity of pro-Casp3 (C3) [39] and of the Casp3–
XIAP complex (C3*X), free active Casp3 (C3*) was taken as
the response in our simulations.
Finally, we included protein synthesis and degradation in
the model (reactions 16–28). More speciﬁcally, the unmodi-
ﬁed proteins A*, C9, X, and C3 are produced with a constant
rate, and all molecular species in Figure 1B are subject to
ﬁrst-order degradation. While the total cellular concentra-
tions of Apaf-1, Casp9, Casp3, and XIAP (i.e., the ratio of
protein synthesis and degradation rates) were measured
[35,50–53], the kinetics of synthesis and degradation were
not known. For simplicity, we assumed the same degradation
rate for all molecular species in the model, and adjusted the
synthesis rates in order to obtain previously measured
protein concentrations (Table 1). This implies that the total
concentrations of Apaf-1, Casp9, Casp3, and XIAP remained
constant throughout our simulations.
From the model described above (Figure 1B), which will be
referred to as the ‘‘wild-type model’’ in the following,
molecular balances could be derived for each considered
molecular species resulting in a system of 13 ordinary
differential equations (Protocol S1). In general, protein–
protein association (reactions 1, 4–6, 7, and 10–13 in Figure
1B) was modeled as a reversible second-order process, and
caspase-mediated cleavage (reactions 2, 3, 8, 9, 14, and 15 in
Figure 1B) was modeled as an irreversible second-order
process. As many similar reactions (e.g., 1 and 13 in Figure 1B)
were assumed to proceed with the same kinetics (see Table 1),
the model comprises 16 kinetic parameters. The unknown
kinetic parameters were set to reasonable values (Table 1) in
order to reproduce the previously reported time courses of
caspase activation (see ‘‘Time Course of Casp3 Activation’’).
Besides the wild-type model, we also analyzed two modiﬁed
models in order to get insights into the mechanisms that are
responsible for bistability in caspase activation. 1) In the
‘‘Casp9-mutant model,’’ which comprises only the black
reactions in Figure 1B, we eliminated Casp3-mediated feed-
back cleavage of Casp9 (reactions 8 and 9 in Figure 1B) from
the wild-type model. 2) Based on available experimental data
(see Discussion), we assumed competitive (i.e., mutually
exclusive) binding of Casp3 and Casp9 to XIAP in the wild-
type model. By contrast, Casp3 and Casp9 were allowed to
bind XIAP simultaneously in the ‘‘noncompetitive model’’;
that is, the wild-type model was extended by four ternary
Casp9-XIAP-Casp3 complexes (Protocol S1).
Time Course of Casp3 Activation
Experiments in cytosolic extracts revealed that exoge-
nously added cyto c induces maximal Casp3 cleavage within
;15 min in some cells [36], while completion takes longer (up
to ;60 min) in other systems [5,6,33,54]. More speciﬁcally, the
Casp3 cleavage seems to be fast upon strong stimulation, but
slower if stimulation is weak [6,53,55].
We were interested whether the model was able reproduce
these observations if previously measured protein concen-
trations of Apaf-1 (20 nM), Casp9 (20 nM), Casp3 (200 nM),
and XIAP (40 nM) were assumed [35,50–53]. Exogenous
addition of cyto c was simulated by a step-like increase in
the total amount of active Apaf-1 monomers, A*tot, as cyto c–
induced apoptosome formation was reported to be a very
rapid process [36,38]. Such a step-input is also expected to
reﬂect input characteristics within living cells reasonably well,
s i n c ec y t ocr e l e a s ef r o mm i t o c h o n d r i aw a ss h o w nt o
complete within 5 min [56,57].
The results shown in Figure 2A reveal that the simulated
time courses of caspase activation agree well with those
measured experimentally, and that simulated response time is
indeed inversely related to the stimulus strength (Figure 2A).
Full activation of all cellular Apaf-1 molecules (A*tot¼20 nM)
elicits fast Casp3 activation, while a critical slowing down is
observed near the threshold (A*tot ; 3 nM; see Figure 2B), as
expected for a bistable system [28,50]. Notably, the slope of
the time courses shown in Figure 2A is only marginally
affected by the onset time of caspase activation (i.e., by the
stimulus level). This is in accordance with experimental
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Bistability in Caspase Activationresults obtained in cyto c–treated cytosolic extracts [5,36,54]
and in single living cells [58], which showed that, once
initiated, Casp3 activation is rapidly completed within less
than 15 min.
Bistability in Caspase Activation
Experimental evidence suggests that cyto c–induced cas-
pase activation can be bistable and irreversible (see Intro-
duction). The simulated steady-state Casp3 activity (C3*) was
indeed bistable and irreversible (Figure 2B, black line). The
system exhibits three steady states, two stable (solid black
lines) and one unstable (dashed black line), for A*tot between
0 and ;3 nM, and shows hysteretic behaviour: starting from
the resting state (point 1), the system retains low Casp3
activity even for increasing stimuli, A*tot, until a threshold
(point 2) is reached, whereby Casp3 activity switches to the
higher steady state (point 3) in an all-or-none fashion. The
system remains at this higher steady state even if the stimulus
is removed (point 4), so that caspase activation is irreversible,
and thus represents the point of no return for apoptosis.
We next addressed the mechanism of bistability, and
hypothesized that Casp3-mediated feedback cleavage of
Casp9 was responsible, since bistability is thought to require
a positive circuit [25]. Therefore, reactions 8 and 9 in Figure
1B were blocked to simulate a mutant Casp9 (D330A), which
is refractory to cleavage by Casp3 (‘‘Casp9-mutant model’’).
Unexpectedly, bistability was retained (Figure 2B, gray line),
which suggests that a hidden positive feedback loop operates
in the Casp9-mutant model.
XIAP Establishes an Implicit Positive Feedback in Caspase
Activation
More detailed simulations revealed that XIAP establishes
an implicit positive feedback in the Casp9-mutant model, and
Figure 3 schematically depicts how this mechanism contrib-
utes to irreversibility in the wild-type model: Upon weak
stimulation (point 1 in Figure 2B) the vast majority of Apaf1-
associated, highly active Casp9 molecules is inhibited by
excess XIAP, so that cleavage of pro-Casp3 is negligible (top
left in Figure 3). As the stimulus strength is increased above
the threshold (point 2 in Figure 2B), active Apaf-1 also
recruits some free Casp9 that is not subject to inhibition by
XIAP, so that Casp3 activation is initiated (top right in Figure
3). Active Casp3 then further promotes its own activation by
sequestering XIAP away from Apaf-1-associated Casp9
(‘‘redistribution’’), so that ﬁnally the vast majority of XIAP
is bound to Casp3 (bottom right in Figure 3). This XIAP
redistribution results a positive feedback loop, which,
together with Casp3-mediated Casp9 feedback cleavage,
suddenly switches the system from low to high Casp3 activity
(transition from point 2 to point 3 in Figure 2B). Caspase
activity is maintained even if the stimulus is removed, as
Casp3, once activated, retains XIAP, and thereby prevents full
Casp9 deactivation (bottom left in Figure 3). Additional
simulations, which corroborate our conclusions regarding
XIAP-mediated feedback can be found in Protocol S2.
In order to determine how the protein concentrations in
the caspase cascade affect bistability, we analyzed the
stimulus–response curves (similar to those in Figure 2) for
varying total Casp3 and Casp9 concentrations. Five types of
qualitative behaviour in caspase activation could be distin-
guished in the physiological range of stimulus concentrations
(A*tot ¼ 0–200 nM): 1) the system is essentially devoid of any
Casp3 activation (monostable–no activation [MN], Figure 4A);
2) Casp3 activation occurs in a gradual manner (monostable–
gradual activation [MG], Figure 4B); 3) the caspase cascade is
bistable-reversible (BR, Figure 4C); 4) Casp3 activation is
bistable-irreversible (BI, Figure 4D); and 5) constitutive Casp3
activity is observed (monostable–basal activation [MB], Figure
4E). The corresponding bifurcation diagram (Figure 4F)
reveals that bistability in the Casp9 mutant model can only
Figure 2. Dynamic and Steady-State Behaviour of the Caspase Cascade
(A) Time course of Casp3 activation (wild-type model) upon a step-like
increase in the amount of active Apaf-1 (A*tot)a tt¼ 0 from zero to the
concentration indicated.
(B) Steady-state stimulus-response curves of the wild-type model (black
line) and of the Casp9-mutant model (gray line), where Casp3-mediated
feedback cleavage of Casp9 does not occur. Stable and unstable steady
states are indicated by solid and dashed lines, respectively.
DOI: 10.1371/journal.pcbi.0020120.g002
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Bistability in Caspase Activationbe observed if the total Casp9 concentration is lower than
that of XIAP (40 nM), which ensures that the system is in the
off-state as long as Casp3 is inactive. In addition, Casp3 must
be signiﬁcantly more abundant than XIAP to sequester it
away from Casp9 (i.e., to establish positive feedback).
Determinants for Bistability and Irreversibility
We next sought to determine the relative contribution of
XIAP-mediated feedback and that of Casp3-mediated feed-
back cleavage (of Casp9) to bistability and irreversibility in
caspase activation. To this end, we compared the bifurcation
plot of the wild-type model (Figure 4G) with those of mutant
models, where we selectively blocked either XIAP-mediated
feedback (Figure 4H; ‘‘noncompetitive model’’) or Casp3-
mediated feedback cleavage (Figure 4F, ‘‘Casp9-mutant
model’’). XIAP-mediated feedback is abolished in the non-
competitive model (Protocol S1), since XIAP was assumed to
be capable of simultaneous binding to Casp3 and Casp9 in
these simulations. As schematically depicted above Figure 4H,
this corresponds to a caspase cascade, which is controlled by
the XIAP fragments BIR1-BIR2 (speciﬁc for Casp3) and BIR3-
RING (speciﬁc for Casp9) rather than by full-length XIAP.
Figure 4F and 4H demonstrate that each feedback mechanism
alone can bring about bistability for experimentally meas-
ured caspase expression levels (interception of dashed lines in
Figure 4F–4H). By contrast, irreversibility is restricted to a
narrow range of caspase concentrations in both mutant
models, and is never observed in the vicinity of experimen-
tally measured caspase expression levels. Importantly, the
wild-type model exhibits robust irreversibility in the physio-
logical range of caspase expression levels, which suggests that
irreversibility in caspase activation requires coordinated
action of both XIAP- and cleavage-mediated feedbacks.
The computational results shown in Figure 4G also explain
why various cell types show qualitatively different patterns of
caspase activation and unravel the underlying mechanisms:
Casp3 activation is efﬁciently inhibited in cells, where the
total XIAP concentration exceeds those of Casp3 and Casp9
(MN; Figure 4A). Gradual Casp3 activation is predicted to
occur in cells, where Casp9 expression is high compared with
XIAP and Casp3 expression (MG, Figure 4B). In this situation
XIAP is effectively sequestered by excess Casp9, and the
remaining free Casp9 molecules efﬁciently cleave Casp3 as if
XIAP was not present. In case that both caspases are
expressed at intermediate levels, the feedback loops discussed
above cooperate to reversibly switch on the system in an all-
or-none fashion (BR, Figure 4D). Even higher caspase
expression levels relieve the cascade from XIAP-mediated
inhibition so that Casp3 can be highly active even in the
absence of stimulation. Such constitutive activation either
arises spontaneously (MB, Figure 4C) or requires previous
suprathreshold Casp3 activation (BI, Figure 4E).
The preceding conclusions could be conﬁrmed by analyz-
ing the qualitative behaviour of caspase activation as a
function of the competition ratio a, and of XIAP expression
(Figure 5). The competition ratio a equals the fold-change in
XIAP’s afﬁnity for Casp9 brought about by Casp3 binding to
XIAP (and vice versa), and thereby quantiﬁes the degree of
competitive caspase binding to XIAP (Protocol S1). Figure 5
demonstrates that the range of bistability is signiﬁcantly
broadened even if the Casp3-binding to XIAP reduces XIAP’s
afﬁnity for Casp9 (and vice versa) less than 5-fold (a . 0.2). By
contrast, reliable irreversibility requires signiﬁcant competi-
tion of caspases for XIAP, at least with the default protein
concentrations (Table 1) we assumed here. As shown in Figure
5, high XIAP levels completely abolish caspase activation
(MN), bistability is observed for intermediate XIAP concen-
trations (BR, BI), and low XIAP levels fail to prevent caspase
activation even in the absence of external stimulation (MB).
Our conclusions regarding the qualitative behaviour of
caspase activation are supported by experimental data. 1)
Overexpression of XIAP abolishes apoptosis and Casp3
activation in response to microinjection of cyto c (type MN)
[59]. 2) overexpression of Casp3 [60,61] or Casp9 [33,62,63]
results in caspase activation and/or apoptosis (type MB). In
contrast, Casp3 overexpression failed to elicit its own
activation in another study [64], and the model suggests that
this may be due to low Casp9 expression (see Figure 4G). 3)
High levels of IAP antagonists such as Smac were shown to
activate the Casp9 ! Casp3 pathway [65,66] and to elicit
spontaneous apoptosis [67], even in cell types that are devoid
of basal cyto c release or Casp8 activation (type MB). The
inability of others to reproduce Casp3 activation by XIAP
Figure 3. Schematic Representation of XIAP-Mediated Feedback
At resting state (top left) Casp9 is efficiently inhibited by XIAP, so that
Casp3 is inactive. Upon stronger stimulation (top right) some Casp9
escapes XIAP-mediated inhibition and activates Casp3, which then
sequesters XIAP away from Casp9 (redistribution). This XIAP redistrib-
ution finally results in strong activation of both Casp9 and Casp3
(bottom right), and retains the system in an active state even if the
stimulus is reduced (bottom left). The numbers on the top of each
scheme correspond to those indicated next to the stimulus-response in
Figure 2B (black line).
DOI: 10.1371/journal.pcbi.0020120.g003
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Bistability in Caspase Activationdepletion or Smac addition [68] is probably due to the fact
that the threshold BI ! MB (Figure 5) was not exceeded in
these studies (e.g., due to the expression of Smac-resistant
IAP proteins such as NAIP [69]). 4) Gradual Casp3 activation
(type MG) was observed in cyto c–treated cytosolic extracts
[8–10], and also in ﬂow cytometric analyses of living cells
[70,71]. 5) The existence of bistable states (types BI and BR) is
supported by all-or-none Casp3 activation in response to cyto
c, and by the fact that Casp3 activation can irreversibly
commit cells to death (see Introduction), although deﬁnitive
proof for these types of behaviour is lacking (see Discussion).
The Mitochondrial Pathway Acts as an Efficient Binary
Integrator
In the previous section, we demonstrated that excess of
XIAP over Casp3 and Casp9 abolishes cyto c–induced caspase
activation even if high concentrations (200 nM) of the
stimulus, active Apaf-1, were assumed (type MN). However,
various experimental studies in cells, where Casp3 activation
was inhibited downstream of cyto c release, have shown that
caspase activation can be rescued by relatively moderate
Apaf-1 overexpression (see [72] and references therein). This
suggests that Casp3 activation does not occur if the
concentration of the bottleneck, active Apaf-1, is below the
threshold stimulus concentration, where the bistable system
switches from the lower to the upper steady state (point 2 in
Figure 2B). In support for such a threshold model, it was
recently shown that a minor (;2-fold) decrease in Apaf-1
expression dramatically decreases caspase activation in
response to cyto c microinjection [72]. These studies also
suggest that the apoptotic threshold can be regulated down-
stream of Apaf-1, as Smac, an inhibitor of XIAP action,
rescued cyto c–induced caspase activation in Apaf1-knock-
down cells [72]. Therefore, we were interested how the
threshold of the bistable cascade is affected by transcriptional
and post-transcriptional regulation of Casp3, Casp9, and/or
XIAP.
The corresponding results are shown in Figure 6: starting
from the default model (point of intersection), the predicted
threshold stimuli, A*tot,T, of the bistable system were plotted
as a function of Casp3 (gray dotted line), Casp9 (gray solid
line), and XIAP (black solid line) expressions. In addition, we
also considered simultaneous alterations of Casp3 and Casp9
to the same relative extent (black solid line) in order to
understand how the apoptotic threshold is affected by nitric
oxide, a covalent inhibitor of Casp3 and Casp9 active sites [1].
These simulations demonstrate that decreasing levels of
Casp3 moderately increase the threshold, A*tot,T,w h i l e
alterations in Casp9 shift the threshold more efﬁciently.
Regulation of XIAP levels is predicted to allow even more
effective control over the apoptotic threshold, and similar
arguments also hold for nitric oxide–mediated inhibition of
both Casp3 and Casp9 [1].
Our results regarding XIAP as an efﬁcient modulator of an
Figure 4. Determinants for Bistability and Irreversibility I
The dose-response curves of the Casp9-mutant model (F), those of the wild-type model (G), and those obtained for noncompetitive caspase binding to
XIAP (H) were analyzed for varying Casp3 and Casp9 expression levels. Five types of qualitative behaviour, which are schematically depicted in (A–E),
could be distinguished in the physiological range of Apaf-1 expression levels (0–200 nM). The light and dark gray areas in (F–H) correspond to the
bistable regions of the model (BR, BI), and the abbreviations MN, MG, and MB indicate the qualitative behaviour outside the bistable region.
Experimentally measured caspase concentrations (see Table 1) are highlighted by dashed lines in (F–H).
DOI: 10.1371/journal.pcbi.0020120.g004
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studies, as a 2-fold drop in XIAP expression was sufﬁcient to
allow cyto c–induced Casp3 activation [73,74]. Moreover,
increasing amounts of Smac, a high-afﬁnity inhibitor of XIAP
(Figure 1B), elicited all-or-none Casp3 activation in cyto c–
treated HeLa cell cytosols [68]. Finally, the threshold cyto c
concentration that is required to achieve switch-like Casp3
activation was shown to be cell-type dependent, and low
thresholds correlated with low IAP expression levels [7]. Our
simulations are also corroborated by the fact that PKB/Akt-
mediated inhibitory phosphorylation of Casp9 completely
abolished cyto c–induced Casp3 activation, even though
Casp9 enzymatic activity was only partially suppressed [63].
In addition, Casp3 overexpression sensitizes cells to apoptosis
in response to cytotoxic stress [64], which is also in
accordance with the simulations shown in Figure 6.
Thus, we can conclude that bistable behaviour in the
mitochondrial caspase cascade serves to compute multiple
regulatory inputs into a binary decision whether caspase
activation occurs or not (‘‘binary integrator’’). Further
calculations, where relative changes in protein expression
were related to relative changes in the threshold stimulus,
A*tot, suggest that the following order of input potency holds
in general: Regulation of active Apaf-1 , Casp3 regulation ,
Casp9 regulation , XIAP regulation ’ simultaneous regu-
lation of Casp3 and Casp9. The simulations also predict that
the apoptotic threshold is essentially constant if all compo-
nents (i.e., Casp3, Casp9 and XIAP) are simultaneously
changed to the same relative extent (Figure 6; black dash-
dotted line). Hence, the life-or-death decision appears to be
remarkably insensitive towards random ﬂuctuations in gene
expression, which are thought to result in correlated changes
in cellular protein levels [75]. In addition, these simulations
suggest that general inhibito r so fp r o t e i ns y n t h e s i so r
degradation, which are known to be inducers of apoptosis
[56,64], do not affect the threshold of the Casp9 ! Casp3
cascade.
Discussion
In the present paper we showed that inhibition of Casp3
and Casp9 by IAPs results in an implicit positive feedback,
since cleaved Casp3 augments its own activation by seques-
tering IAPs away from Casp9 (Figure 3). In addition, we
demonstrated that XIAP-mediated feedback cooperates with
Casp9 cleavage by Casp3 to bring about bistable and
irreversible Casp3 activation in the range of experimentally
measured kinetic parameters and protein concentrations
(Figures 2, 4, and 5).
Model Assumptions
XIAP-mediated feedback can only be observed if Casp3 and
Casp9 compete for binding to XIAP at least to some extent
(Figures 3 and 5). Such competition is supported by the fact
that Casp3 and Casp9 cannot be co-immunoprecipitated in
cells [35]. Casp3 (and not only Casp9) is recruited to the
apoptosome at least in some cells [35], and it is conceivable
that this occurs by means of a sequential Apaf1-Casp9-XIAP-
Casp3 complex. Even if such a complex exists, it seems to be
rather instable, as Casp3 can be eluted from the apoptosome
(i.e., from Apaf-1) by low ionic strength [39], while much
higher ionic strength is required to elute Casp9 [32]. Recent
co-immunoprecipitation experiments revealed the existence
of a ternary Casp9-XIAP-Casp3 complex in vitro [76].
However, only minor amounts of Casp3 were found in the
complex even if XIAP was incubated with excess Casp3 and
Casp9. Taken together, these data suggest that Casp3 and
Casp9 signiﬁcantly compete for binding to XIAP.
Co-immunoprecipitation studies with Casp3, Casp9, and
XIAP might underestimate the degree of competition of
caspases for a single XIAP molecule (i.e., XIAP-mediated
feedback), as IAP family members are often homodimers. In
case that each XIAP molecule in a dimer independently
couples to caspases, a ternary Casp9–XIAP–Casp3 complex
will be seen, even if Casp3 and Casp9 compete for a single
XIAP molecule. Therefore, we propose to directly test for
XIAP-mediated feedback in vitro. As further outlined in
Protocol S3, a Casp9 mutant (D330A), which is refractory to
Casp3-mediated feedback cleavage, should be incubated with
active apoptosomes and XIAP either in the presence or in the
absence of pro-Casp3. Coincubation with XIAP alone is
expected to result in low Casp9 activity [34], but excess pro-
Casp3 should reverse this inhibition by sequestering XIAP
away from Casp9.
We have also assumed in the model that XIAP inhibits all
forms of Casp9 (i.e., that the afﬁnity between Casp9 and XIAP
is not affected by either Casp9 autocleavage [at Asp-315] or
Casp3-mediated feedback cleavage of Casp9 [at Asp-330]).
While it is clear that autoprocessed Casp9 (cleaved at Asp-315
only) is efﬁciently inhibited by XIAP [34,47,49,51,77], some
Figure 5. Determinants for Bistability and Irreversibility II
The qualitative behaviour of caspase activation according to Figure 4A–
4E is shown as a function of the XIAP level, and of the competition ratio
a. The competition ratio a (Protocol S1) equals the fold-change in XIAP’s
affinity for Casp9 brought about by Casp3 binding to XIAP (and vice
versa), and thereby quantifies the degree of competitive caspase binding
to XIAP as indicated on the top.
DOI: 10.1371/journal.pcbi.0020120.g005
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uncleaved pro-Casp9 [34,47,78], at least partially [77,79], but
others could not reproduce these results [49,51]. As explained
in the context of Figure 3, bistability requires that XIAP binds
to and inhibits Apaf1-activated Casp9 upon weak stimulation,
so that low Casp3 activity can be maintained. Importantly,
such XIAP-mediated control over Casp9 activity will be
ensured even if XIAP does not associate with uncleaved pro-
Casp9, since pro-Casp9 recruitment to the apoptosome was
shown to result in its fast and complete autoprocessing (at
Asp-315) [38,39]. Casp3-mediated feedback cleavage (at Asp-
330) was reported to relieve Casp9 from inhibition by XIAP
[51], and might thereby establish an additional positive
feedback, which would further broaden the ranges of
bistability and irreversibility. As other experimental studies
do not support the existence of this additional feedback
[34,49], we have made the conservative assumption that XIAP
inhibits feedback-cleaved Casp9, too.
In our core model of the intrinsic pathway we considered
only Casp3 and XIAP, but not functionally redundant
molecules. For example, Casp7, which is activated by Casp9
[5], also mediates XIAP-mediated feedback, since it efﬁciently
binds to IAPs [46]. Likewise, molecules such as c-IAP1, c-IAP2,
and NAIP are functionally redundant to XIAP, as they inhibit
both Casp3 and Casp9 [2,69]. In case such functionally
redundant proteins are expressed, the protein concentra-
tions varied in our simulations (e.g., C3tot in Figure 3F–3H)
represent combinations (e.g., sums) of functionally redundant
protein concentrations (e.g., C3tot and C7tot), so that the
results given in the paper continue to hold.
Input Signals
We used the concentration of active Apaf-1 assembled into
apoptosomes as the varying input signal in our simulations,
rather than the amount of cyto c released from mitochondria.
This seems justiﬁed, as available experimental evidence
suggests that apoptosome formation increases gradually with
increasing cyto c concentration [10,37], and that signal
ampliﬁcation occurs in the caspase cascade considered in this
paper [10]. Ourmodel explains how cells reject erroneous cyto
c release from single mitochondria, and also predicts that
reversible cyto c release can elicit irreversible caspase
activation. It should be noted that cyto c release upon
apoptotic stimulation was reported to be all or none under
many [56,57] but not all [80,81] circumstances. Importantly,
dose-response curves using active Apaf-1 as the input (e.g.,
Figure 2B) are physiologically relevant even if cyto c release is
all or none, as they help to explain why caspase activation is
completely abolished for limiting Apaf-1 expression (see [72]
and references therein). More generally, the model provides
insights into how the intrinsic pathway integrates multiple
regulatory inputs including including cyto c release, cyto c
sequestration [39], transcriptional regulation of Apaf-1 [72],
Apaf-1 sequestration [39], transcriptional regulation of IAPs
[2], Smac-mediated IAP sequestration [2], Casp9 phosphor-
ylation [63], and caspase S-nitrosylation [1]. As shown in
Figure 6, the caspase cascade acts as a binary integrator in the
range of bistability (BI and BR in Figures 4 and 5). In contrast,
gradual integration will be seen if the system resides in the
monostable–gradual activation range, and this is particularly
relevant for apoptotic stimuli that directly regulate caspase
cascade members (e.g., Apaf-1) in addition to releasing cyto c
(‘‘feedforward regulation’’). For example, p53 is known to
induce Apaf-1 expression [82], and thereby can elicit gradual
Casp3 activation even if cyto c release is all or none.
Alternatively, gradual Casp3 activation, which was seen in
ﬂow cytometric analyses of living cells [70,71], may be due to
cell-to-cell variability in the intrinsic pathway. Such cellular
heterogeneity seems to be signiﬁcant, as cyto c injection alone
or in combination with Smac does not elicit Casp3 activation
[83] or cell death [59,84] in all cells of a population. Our model
provides a reasonable basis for further studies that focus on
cell-to-cell variability in the intrinsic pathway.
In the Results section, we referred to experimental studies
where Smac, a competitive, high-afﬁnity inhibitor of IAP
binding to caspases [85], was either added to cytosolic extracts
or microinjected into living cells. In living cells, Smac is
eventually released simultaneouslywith cytoc frommitochon-
dria[2](seeFigure 1A).Importantly,such physiological release
of Smac simply corresponds to decreasing XIAP levels in our
model,asmostexperimentswithcaspaseinhibitorshaveshown
that Smac release does not require caspase-mediated feedback
[57,86–88]. Thus, the results shown in Figure 6 explain why
simultaneous release of cyto c and Smac is required to elicit
Casp3 activation in many cell types (e.g., [83]), and predict that
these two stimuli are integrated in an all-or-none manner.
Upstream, Downstream, and Feedback Signaling
In accordance with previous experimental studies (see
Introduction), we showed that, depending on the protein
Figure 6. Binary Integration of Multiple Inputs
The threshold stimulus, A*tot,T, where the bistable system switches from
the lower to the higher steady state (point 2 in Figure 2B), is plotted as a
function of Casp3 (gray dotted line), Casp9 (gray solid line), or XIAP
(black dashed line) expression. In addition, the impact of simultaneous
alterations of Casp3 and Casp9 (black solid line) or of Casp3, Casp9, and
XIAP (black dash-dotted line) to the same relative extent is shown. The
intersection of the graphs corresponds to the default protein concen-
trations (see Table 1). The terms ‘‘linear,’’ ‘‘quadratic,’’ and ‘‘quartic’’
indicate the relationship between protein expression and the apoptotic
threshold, A*tot,T.
DOI: 10.1371/journal.pcbi.0020120.g006
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irreversibly commits cells to apoptosis (BI regions in Figures 4
and 5). However, some cells die by a delayed and morpholog-
ically distinct form of cell death, so-called caspase-independ-
ent cell death, even if caspases are inhibited [89]. Because
caspase-independent cell death is thought to be initiated at
the level of mitochondria, our simulations do not unravel the
determinants for commitment to death in these cells, but only
those for commitment to the fastest death pathway (i.e.,
apoptosis). As the precise kinetics of cell death may, for
example, be important in development [89], our results are
likely to be relevant even in cells subject to caspase-
independent cell death. The physiological importance of the
caspase cascade considered in our model is further supported
by the fact that Apaf-1, Casp9, and Casp3 knockout mice show
morphological defects and die early in development [89]. In
addition, caspase inhibition (e.g., due to IAP overexpression)
allowed for long-term cellular survival and mitochondrial
recovery in response to cytotoxic stress [19–23] and/or after
cyto c was released [11,13,15].
Other positive feedbacks than those included in the model
have been described in the literature. For example, Casp3 was
shown to induce processing of Casp6, which in turn cleaves
Casp8, an activator of Casp3 [5] (feedback 1 in Figure 1A). In
our opinion, this feedback is unlikely to account for bistable
Casp3 activation via the intrinsic pathway, since Casp3
activation in response to cyto c is unaffected when the
delayed Casp6 ! Casp8 pathway is abrogated [5]. This
conclusion is likely to hold in general, as Casp8 cleavage
alone is not sufﬁcient to stimulate its catalytic activity, but
recruitment to the death-inducing signaling complex (i.e.,
ligand-binding to death receptors) is required [62].
It has been suggested that active Casp3 ampliﬁes cyto c
release from mitochondria by directly cleaving upstream
regulators such as Bid and Bcl-2 (feedbacks 2 and 3 in Figure
1A), or by cleaving modulators of these Bcl2-family members
such as Mekk1 [1]. However, the relevance of this feedback for
the intrinsic pathway remains unclear, as experiments with
caspase inhibitors revealed that cyto c release is caspase-
independent in most cell types (e.g., [4,11,49,56,57,77]).
Furthermore, the concept of Casp3-induced cyto c release
is inconsistent with the fact that Casp3 activation fails in
various cell types even though large amounts of cyto c were
released from mitochondria (see [72] and references therein).
XIAP was shown to be cleaved by Casp3 and/or Casp8 in
response to apoptotic stimulation, and such XIAP processing
may result in autoampliﬁcation of Casp3 activity (feedback 4
in Figure 1A) [90,91]. In line with a predominant role of
Casp8, cleavage of XIAP seems to be especially pronounced
when cells are subjected to death-receptor stimulation
[90,91]. By contrast, moderate [91], minor [35,36], or even
no XIAP processing [92,93] was seen in response to apoptotic
stimuli that initiate apoptosis via the intrinsic pathway. In
addition, Casp3 may also establish a positive feedback loop by
cleaving inhibitors of XIAP auto-ubiquinitation and protea-
somal degradation such as PKB/Akt (feedback 4 in Figure 1A)
[94,95]. Accordingly, the total XIAP abundance was shown to
decrease during apoptosis (e.g., [95]), but this seems to be a
cell-type–speciﬁc phenomenon, as the total amount of full-
length XIAP remains essentially unchanged [91–93] or even
increases [96] in other models of apoptosis.
Because of these data and due to the fact that most
molecular species of the caspase cascade were shown to be
continuously synthesized during apoptosis [96,97], we as-
sumed constant total protein concentrations in our model. In
order to get insight into how Casp3-mediated XIAP degra-
dation affects the behaviour of our model, we also imple-
mented an extended model, which takes such regulation into
account (Protocol S4). Importantly, Casp3-mediated feedback
cleavage of XIAP did not result in physiologically relevant
bistability in a system devoid of other feedback ampliﬁcation
loops (Protocol S4). In addition, the qualitative conclusions
drawn from Figures 2, 4, and 5 were still valid when XIAP-
mediated feedback was included in the wild-type model
(Figure 1B). However, these calculations also indicated that
Casp3-mediated XIAP degradation may cooperate with the
feedback loops discussed above, as it lowered the apoptotic
threshold, A*tot,T, and signiﬁcantly broadened the range of
XIAP concentrations, where caspase activation is irreversible
(BI in Figure 5).
Active Casp3 cleaves a variety of cellular substrates, and
thereby initiates the execution phase of apoptosis [1].
Experimental evidence suggests that Casp3 activates multiple
execution pathways in parallel and not in a sequential,
cascade-like manner, since mutational inactivation of Casp3
cleavage sites abrogates speciﬁc features of apoptosis depend-
ing on the target mutated [1]. Some Casp3 substrates (e.g.,
PARP) are cleaved almost simultaneously with Casp3, while
the processing of others (e.g., Topo I) is delayed by several
hours [98,99]. Taken together, these data suggest that
transient activation of the branchpoint molecule, Casp3,
elicits a partial apoptotic program, which might lead to
potentially harmful cellular deregulation or tissue inﬂamma-
tion. Active Casp3 is known to be a rather unstable protein
[100], which suggests that irreversible behaviour of the
caspase cascade is required to maintain Casp3 activation if
upstream stimuli are removed. Experimental evidence indeed
suggests that such transient stimulation occurs in living cells.
1) Cyto c release from mitochondria is thought to be a
reversible as long as mitochondrial membrane potential is
maintained. Because the mitochondrial membrane potential
can remain unchanged long after caspases have been
activated [3,4], cytosolic cyto c (i.e., the stimulus) will decline
as soon as the apoptotic trigger is removed.
2) Experiments with antibodies towards the caspase-
activating form of cyto c, holo–cyto c, revealed that holo–
cyto c is rapidly degraded after its release into the cytosol
[17].
The irreversibility mechanisms described in this paper
ensure that apoptosis will fully proceed even after a decline in
cyto c, and render apoptotic execution program insensitive
towards survival signaling once apoptosis has been initiated.
Such insensitivity is then further enhanced by delayed Casp3-
mediated cleavage and thereby inactivation of various
antiapoptotic signalling proteins [94].
Proposed Experimental Verification of Bistability
Our predictions regarding all-or-none and binary integra-
tion of multiple inputs behaviour in caspase activation
(Figures 2–5) can be addressed experimentally by analyzing
Casp3 activation in cytosolic extracts or on a single-cell level.
In cytosolic extracts, depletion and readdition experiments
with various Apaf-1, Casp3, Casp9, and/or XIAP concentra-
tions should result in all-or-none caspase activation in the BR
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Casp3 substrates must be chosen carefully if enzymatic
activity is used as a readout. Alternatively, such multivariate
analyses can be performed by microinjecting these proteins
together with cyto c and/or Smac into living cells. Caspase
activation can then be determined using antibodies against
active Casp3 either in ﬂow cytometric measurements or in
immunoﬂuorescence microscopy. Bistability should be con-
ﬁrmed by adding cyto c in combination with appropriate
antagonists such as anti–cyto c antibodies, apo–cyto c, or
diarylureas, which are known to inhibit apoptosome activity
[18,101]. In the range of bistability, simultaneous addition of
suprathreshold cyto c levels and sufﬁcient amounts of
antagonist should yield low Casp3 activity, while strong
caspase activation should be observed if the antagonist is
added after cyto c. Subsequent addition of a Casp9 inhibitor
would break the feedback loops discussed in the paper, and is
therefore expected to reverse Casp3 activation. The bist-
ability measurements described above can be done on a
population level (i.e., by Western blotting) if caspase
activation is irreversible, but require single-cell tracking
methods (e.g., real-time Casp3 assays or ﬂow-cytometric cell
sorting) in the bistable-reversible range.
Concluding Remarks
In conclusion, we have presented a theoretical framework
for quantitative experimental analyses of the intrinsic
apoptosis pathway. Previous mathematical models differ
from the present study in 1) the choice of apoptotic pathways,
2) the network properties focused on, and 3) the cell types
analyzed. Bentele et al. [102] and Eissing et al. [50]
concentrated on the extrinsic apoptosis pathway (see Figure
1A), and analyzed how switch-like behaviour arises due to
stoichiometric inhibition [102] or due to positive feedback
[50]. Fussenegger et al. [103] have implemented a large-scale
model of both intrinsic and extrinsic pathways, and analyzed
time course behaviour rather than bistability and apoptotic
thresholds. Bagci et al. [104] focused on how Casp3-mediated
feedback cleavage of Bcl2-family members (feedbacks 2 and 3
in Figure 1A) contributes to bistability in the intrinsic
apoptosis pathway. As discussed above, these feedbacks
appear to be restricted to particular cell types, where they
might cooperate with those discussed here. Finally, Stucki and
Simon [105] concentrated on the regulation of Casp3
degradation. The mechanisms proposed in the present paper
may be combined with those discussed by Bagci et al. [104]
and by Stucki and Simon [105] in order to implement more
realistic models of the intrinsic apoptosis pathway.
As summarized in Protocol S5, cellular inhibitory proteins
such as stoichiometric inhibitors, phosphatases, and GTPase-
activating proteins frequently inhibit consecutive intermedi-
ates in cellular signaling cascades. In general, positive
feedback and bistability can arise in this ‘‘shared inhibitor
motif’’ if: 1) the signalling intermediates compete for binding
to the inhibitor at least to some extent; 2) only the active form
of the downstream intermediate (e.g., Casp3), but not its
inactive precursor (pro-Casp3), binds to the inhibitor; and 3)
the downstream intermediate (e.g., Casp3) is more abundant
than the inhibitor (e.g., XIAP), which in turn needs to exceed
the upstream intermediate (e.g., Casp9). As available exper-
imental data are in accordance with these requirements, the
feedback mechanism described in this paper is likely to be a
widespread principle on how cells achieve ultrasensitivity,
bistability, and irreversibility (Protocol S5).
Materials and Methods
All numerical simulations were done using the MatCont Toolbox
within the MATLAB (The Mathworks, Natick, Massachusetts, United
States) computing environment. SBML codes of the wild-type and
noncompetitive models are available in Protocols S6 and S7).
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